Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that RASSF1A promoter polymorphisms affect RASSF1A expression, further contributing to the genetic susceptibility to lung cancer.
|
18313166 |
2008 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A cross-sectional study was conducted in which the methylation status of DAPK, CDKN2A (p16) and RASSF1A genes in sputum and bronchial washing (BW) from subjects at risk for LC was analyzed.
|
25069886 |
2014 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the RASSF1 Ala133Ser SNP is associated with development of lung cancer, especially of lung adenocarcinoma.
|
16125301 |
2006 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that starting smoking under age 18 is an independent risk for RASSF1A hypermethylation, thus identifying a molecular alteration related to the epidemiologic effect of teenage smoking as a lung cancer risk.
|
15540210 |
2005 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests, for the first time, that RASSF1A Ala133Ser polymorphism may contribute to cancer susceptibility, especially for lung cancer.
|
24870779 |
2014 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The overall results suggested that smokers with lung cancer had a 1.297-fold (95% CI: 1.066~1.580, p=0.010, p=0.087) higher risk for RASSF1A gene hypermethylation than the non-smokers.
|
25339045 |
2014 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Previously, the RASSF1A, BLU and SEMAPHORIN 3B (SEMA3B) candidate tumor suppressor genes on chromosome 3p21.3 were found to be inactivated and downregulated by genetic and epigenetic changes in lung cancer.
|
15704097 |
2005 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Three bona fide lung cancer tumor suppressor genes namely RBSP3 (AP20 region),NPRL2 and RASSF1A (LUCA region) were identified in the 3p21.3 region.
|
20193080 |
2010 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The risk model showed that 36% of lung cancer patients were defined as "high risk" (≥ 60% chance on lung cancer) based on RASSF1A hypermethylation in Set 1.The model was reproducible in Set 2.
|
24598366 |
2014 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using quantitative methylation-specific PCR, we found that the index of methylation (IM), calculated as IM = 100 × [copy number of methylated/(copy number of methylated + unmethylated gene)], for the RASSF1A and RARB2 genes in the cirDNA isolated from blood plasma and cell-surface-bound cirDNA was elevated 2- to 3-fold in lung cancer patients compared with healthy donors.
|
23806794 |
2013 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
RASSF1A, a recently identified candidate tumor suppressor gene, was found to be inactivated in lung cancer and other tumor types.
|
14506151 |
2003 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We determined the frequency of aberrant promoter methylation of the p16, adenomatous polyposis coli (APC), H-cadherin (CDH13), glutathione S-transferase P1 (GSTP1), O6-methylguanine-DNA-methyltransferase (MGMT), retinoic acid receptor beta-2 (RAR beta), E-cadherin (CDH1), and RAS association domain family 1A (RASSF1A) genes in 198 tumors consisting of small cell lung cancers [SCLCs (n = 43)], non-small cell lung cancers [NSCLCs (n = 115)], and bronchial carcinoids (n = 40).
|
12467239 |
2001 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
L1RE1 in combination with either RARB or RASSF1 could function as biomarkers for separating lung cancer and non-cancerous tissue and could be useful for samples of limited size such as biopsies.
|
29851970 |
2018 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The alternative transcript (RASSF1a) has been shown to be inactivated by hypermethylation in several human malignancies, including breast, prostate, and lung cancer, and in cutaneous melanoma.
|
17251440 |
2007 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of the study was to explore the application of artificial neural network model in the auxiliary diagnosis of lung cancer and compare the effects of back-propagation (BP) neural network with Fisher discrimination model for lung cancer screening by the combined detections of four biomarkers of p16, RASSF1A and FHIT gene promoter methylation levels and the relative telomere length.
|
27766520 |
2017 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
RASSF1A is validated as diagnostic marker in lung cancer.
|
25719833 |
2015 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The RASSF1A gene is epigenetically inactivated in a large percentage of human lung cancers, in particular small cell carcinomas.
|
12222680 |
2002 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
CTD_human |
DNA methylation markers and early recurrence in stage I lung cancer.
|
18337602 |
2008 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The panel of <i>RASSF1A, 3OST2</i> and <i>PRDM14</i> detected 28% (95% CI 11% to 44%) of lung cancer cases within 2 years, with specificity of 90% (95% CI 86% to 94%).
|
27496969 |
2017 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The methylation ratios for the three genes were significantly higher in LC than in MPM (RASSF1A, P = 0.039; p16(INK4a), P = 0.005; and RARβ, P = 0.002).
|
22146010 |
2012 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to establish the frequency of K-ras and p53 mutations and p16(INK4A), RASSF1A, and NORE1A hypermethylation in sputum of a large cohort of cancer-free heavy smokers and to assess whether these markers are suitable for a routine use in the clinical practice for the early diagnosis of pulmonary cancer.
|
18347195 |
2008 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transfection of RASSF1A suppressed the growth of lung cancer cells in vitro and in nude mice.
|
11429703 |
2001 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
To identify the significance of a support vector machine (SVM) model and a decision tree (DT) model for the diagnosis of lung cancer combined with the detection of fragile histidine triad (FHIT), RAS association domain family 1 (RASSF1A) and cyclin-dependent kinase inhibitor 2A (p16) promoter methylation levels and relative telomere length (RTL) of white blood cells from peripheral blood DNA.
|
27716889 |
2017 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings suggest that serum RASSF1A hypermethylation is a promising molecular biomarker for lung cancer diagnosis.
|
17267069 |
2007 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
RASSF1A, a tumor suppressor gene, is frequently inactivated in lung cancer leading to a YAP-dependent epithelial-mesenchymal transition (EMT).
|
30979377 |
2019 |